RNA Analytical/Quality Articles

  1. Why RNA–LNP Development Needs Higher-Resolution Analytics In 2027 9/11/2026

    Raising analytical resolution is among the cheapest interventions available. With regulators tightening and capital selective, it is also among the most consequential.

  2. What Oligo Manufacturing Risks Are We Underestimating? 9/8/2026

    Earlier this year, I attended the OPT Congress, where I had the great fortune of meeting consultant Marc Lemaitre. I recently sat down with Lemaitre for a follow-up interview to gauge some of the evolutions he’s been watching within the CMC landscape for oligo development. Here, he digs into the shifts in quality he’s noted, pointing out some of the potential pitfalls we may encounter in our manufacturing that could stand to impact the overall quality of our oligos. 

  3. Will 2027 See A Meteoric Rise Of Programmable Nanomedicine? 9/2/2026

    The significance of programmable nanomedicines is not simply that nanoparticles can carry more functions. It is that biological information can become part of the control logic.

  4. From Cell State Reprogramming To The Clinic: Turning The Regulatory Genome Into RNA Medicines (Pt. 2) 8/26/2026

    Ounzain discusses how regulatory genome biology is being translated into drug discovery, from identifying lncRNA targets to building clinically relevant therapeutics and more.

  5. From Baby KJ To Global Access: The 3 Pillars Of Next-Gen mRNA Expansion 8/8/2026

    Obviously, the transition from RNA vaccines to therapeutics is an “expansion” all on its own; but to do this successfully, we need to expand our science, our products’ deliverability, and our patient access. In the following article, I highlight a few of the best practices and/or innovations that came up in conversation during this event that will play a significant role in helping us expand mRNA’s reach, both scientifically and therapeutically.

  6. Building A Self-Driving Lab For LNP Development 7/20/2026

    With commercially available components, MIT researchers built a platform that accelerates LNP process development, optimization, and autonomous manufacturing research.

  7. 5 Critical Regulatory Topics To Watch In The Oligo Sector 7/16/2026

    Though our guidances have helped us achieve upwards of 20 commercially approved oligo products, as I listened to GSK’s director of CMC policy and advocacy, Katie Duncan, present at TIDES, it struck me just how far we have yet to come. Here, I single out a few of the biggest topics of regulatory discussion shaping the oligo therapeutics market.

  8. Reassessing Nanoparticle Immunotoxicity: From Well-Established To Novel Approaches 7/14/2026

    This article highlights government-funded resources available to de-risk nanomedicines, reviews principles of immunotoxicity testing, and discusses emerging methodologies.

  9. Can Oligonucleotide Regulations Keep Up With Manufacturing Innovation? 7/1/2026

    Here in part 2 of my TIDES takeaways, I’ll unpack which guidances we have at our disposal today in the oligo world, and what we can expect in the future. 

  10. Stay "Stereocurious": What The Future Holds For Oligo Quality 6/22/2026

    Overall, there were two areas of discussion at TIDES that demonstrate the amount of growth we have yet to do as a space — particularly in the realms of regulatory development and quality. As I intend to showcase here in part 1 of this muti-part article, this year’s TIDES was a great reflection of the tension(s) that can arise as we realize how much space exists between where we are and where we’re going next.